• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

SARS-CoV-2's exploitation of the EMMPRIN-receptor and potential inhibitors

Cipher

Administrator
Messages
867
It seems like the SARS-CoV-2 virus can invade host cells not only via the ACE2 receptor, but also via a receptor called CD147. [1] This receptor is also called "extracellular matrix metalloproteinase inducer" (EMMPRIN) or Basigin. [2] EMMPRIN/CD147 induces the production of matrix metalloproteinases (MMP) such as MMP-9 and MMP-2 [3] [4]. After some research I've found two potential EMMPRIN/CD147 inhibitors:

Doxycycline

Doxycycline reduced the expression of CD147 and inhibited MMP-2 & MMP-9 activity in an in vitro study. [5] Doxycycline have been shown in human trials be a broad-spectrum MMP inhibitor. [6]

EGCG

EGCG (found in green tea) have been shown to inhibit the expression of EMMPRIN and MMP-9 in an in vitro study. [7] In a mouse study intraperitoneally injected EGCG was found to decrease the expression levels of MMP-2, MMP-9, and EMMPRIN. [8] EGCG is notorious for its low bioavailability, which could mean the studies above aren't applicable for normal oral dosages. However, this doesn't seem to be the case.

In a rat study, 20 mg EGCG per day was administered orally in the context of abdominal aortic aneurysm.[9] Rats seems to have the same low absorption of EGCG as humans [10].
Results:
The abdominal aortic diameter was significantly smaller in the EGCG group than in the control group on day 28(2.960.2 vs 2.360.1 mm;P<.0001). The medial layer wall thickness and elastin content were significantly greater in the EGCG group than in the control group on day 28 (68.4613.6 vs 46.7613.4mm[P<.001] and 20.364.6 vs 9.563.6%[P<.0001], respectively). Gene expression levels of tropoelastin and lysyl oxidase were significantly higher in the EGCG group immediately before AAA induction, indicating promoted elastoregeneration by EGCG administration (tropoe-lastin: 0.5960.36 control vs 1.2460.36 EGCG [P<.05], lysyl oxidase: 0.7760.45 control vs 1.3460.4 EGCG [P<.05])(fold increase). Gene expression levels of inflammatory cytokines, including tumor necrosis factor-a and interleukin-1b, were significantly downregulated in the EGCG group (1.8260.71 vs 0.9760.59 [P<.05] and 3.9163.24 vs 0.8960.59[P<.05], respectively). On day 7, gene expression levels and gelatinolytic activity of matrix metalloproteinase 9 were significantly lower in the EGCG group (1.4160.86 vs 0.5160.42 [P<.05] and 1.0060.17 vs 0.2960.12 [P<.0001],respectively), whereas gene expression levels of tissue inhibitors of metalloproteinase-1 were significantly higher in theEGCG group (0.9660.11 vs 1.1460.09;P<.05).

Conclusions:
EGCG attenuated AAA progression in a rat model by preserving the aortic thickness and elastin content of the medial layer through regeneration of elastin, as mediated by anti-inflammatory effects, and subsequent reduction of matrix metalloproteinase activity.

The dosage was the equivalent of 0.04 mg EGCG/g body weight/day. If you convert that to a human dose (0,04/6,2[11] = 0,006452mg/g human dose = 6.452 mg/kg human dose) it translates to 452 mg oral EGCG/day for someone who weighs 70kg.

In a human study, breast cancer patients undergoing radiotherapy ingested 400 mg oral EGCG x3 / day for several weeks. The levels of serum active MMP-9 decreased by an average of 31% at week 2 and 55% at week 8. The levels of serum MMP-2 zymogens decreased by an average of 22% at week 2 and 51% at week 8. [12]

The mechanism of action for the reduction of MMP-2 and MMP-9 by EGCG in humans might be via the reduction of EMMPRIN/CD147, but that's just speculation on my part.

EGCG have also been shown to have antifibrotic effects in a human study testing 600 mg oral EGCG/day in patients with pulmonary fibrosis undergoing lung biopsy. [13] This mean that EGCG, apart from potentially having an antiviral effect against the SARS-CoV-2 virus, might reduce the risk of lung scarring from COVID-19.

EGCG doses <800mg/day have not shown any hepatotoxic effects according to the European Food Safety Authority[14]:
From the clinical studies reviewed there is no evidence of hepatotoxicity below 800 mg EGCG/day up to 12 months.

An online seller of various nootropic compounds called Nootropics Depot (has a very good reputation when it comes to quality & purity on /r/nootropics) sells a decaffeinated green tea extract containing 45% EGCG for a good price here (10% discount code: REDDITS).